Q/C Technologies Hands PharmaCyte a 49.99% Conversion Cap and Extends Series H Maturity to Sept 2027
QCLS is trading near its 52-week low of $0.275 (1.8% below the low).
Summary
Q/C Technologies amended its Series G and Series H preferred charters to give PharmaCyte a 49.99% ownership cap and pushed the Series H maturity from March 2027 to September 2027. The changes were approved by written consent of the majority preferred holder, not a stockholder vote.
Key Events · Financing and Capital Events · QCLS
-
PharmaCyte Blocker Raised to 49.99%
Series G and Series H certificates of designation now cap PharmaCyte at 49.99% of outstanding common, versus 4.99% for all other holders. The same 49.99% ceiling was written into the Series G Long-Term Warrants.
-
Series H Maturity Pushed to Sept 2027
The Series H maturity date moves from March 2, 2027 to September 2, 2027 under the Series H Maturity Amendment filed with the Delaware Secretary of State on November 20, 2026.
-
Charter Amendments Need No Stockholder Vote
Sections 31(b) and 32(b) were rewritten so the Required Holders can amend the charters by written consent alone, removing the prior stockholder-approval language.
-
Related-Party Control Concentrates
PharmaCyte holds at least a majority of both preferred series and is the sole signatory to the Omnibus Amendment Agreement, giving it unilateral control over future charter changes.
Analysis · QCLS · Life Sciences
PharmaCyte, already the majority holder of both preferred series, now gets a 49.99% beneficial ownership ceiling instead of the 4.99% standard blocker, and the Series H maturity moves out six months to September 2, 2027. The charters were also rewritten so the Required Holders can amend them by written consent without a separate stockholder vote. For a company trading near its 52-week low with a Nasdaq sub-$1 notice already outstanding, this concentrates control of the capital structure in one related party and clears the path for a much larger conversion-driven share issuance than the old 4.99% cap allowed. No shares were issued in this filing — this is permission, not dilution that has occurred.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, QCLS was trading at $0.27 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.4M. The 52-week trading range was $0.28 to $8.17. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.